Comerica Bank Has $30.02 Million Stock Position in Insulet Corporation $PODD

Key Points

• Comerica Bank reduced its stake in Insulet Corporation by 6.5% in Q1, holding approximately 114,324 shares valued at $30.02 million.
• Barclays raised its target price for Insulet shares from $266.00 to $300.00, while Jefferies and Truist Financial have maintained "buy" ratings with target prices of $365.00 and $350.00, respectively.
• In its latest earnings report, Insulet reported a 32.9% year-over-year revenue increase, with earnings of $1.17 per share surpassing expectations by $0.25.

Comerica Bank lowered its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 6.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 114,324 shares of the medical instruments supplier's stock after selling 8,010 shares during the period. Comerica Bank owned approximately 0.16% of Insulet worth $30,023,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of PODD. Dimensional Fund Advisors LP grew its stake in Insulet by 42.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 289,507 shares of the medical instruments supplier's stock valued at $75,588,000 after buying an additional 86,505 shares during the last quarter. Stifel Financial Corp grew its position in shares of Insulet by 167.2% during the 4th quarter. Stifel Financial Corp now owns 28,126 shares of the medical instruments supplier's stock worth $7,343,000 after purchasing an additional 17,599 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Insulet by 0.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 202,728 shares of the medical instruments supplier's stock worth $52,927,000 after purchasing an additional 744 shares in the last quarter. Integrated Wealth Concepts LLC grew its position in shares of Insulet by 39.1% during the 4th quarter. Integrated Wealth Concepts LLC now owns 3,562 shares of the medical instruments supplier's stock worth $930,000 after purchasing an additional 1,001 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Insulet during the 4th quarter worth approximately $371,000.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PODD shares. Barclays increased their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research report on Tuesday, May 13th. Truist Financial initiated coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 target price on the stock. Finally, Raymond James Financial reiterated an "outperform" rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and an average target price of $332.71.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $330.77 on Monday. The company has a market cap of $23.28 billion, a price-to-earnings ratio of 100.54, a PEG ratio of 2.77 and a beta of 1.35. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a 50 day simple moving average of $300.94 and a 200 day simple moving average of $285.90. Insulet Corporation has a one year low of $180.31 and a one year high of $334.18.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's revenue was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.